GLP-1 Super Bowl Ads & The FDA Crackdown: What Changing Ads Mean for Compounded GLP-1s

By GLPeak Team · 2026-02-11

From Super Bowl buzz to FDA scrutiny: find out why top telehealth brands are no longer directly advertising their GLP-1 pens and what it means for the future of weight loss.

Almost 125 million people tuned into the Super Bowl this past weekend. However, in a massive shift from tradition, health and pharmaceutical ads dominated the commercial breaks, turning the biggest night in television into a battleground for your medical attention.

We saw Novo Nordisk flex its budget with a celebrity-packed spot for Wegovy featuring everyone from Kenan Thompson to DJ Khaled, loudly announcing their new pill form, something we've discussed at length. We saw Ro make headlines with Serena Williams openly discussing her weight loss journey on GLP-1s. We even saw Novartis using NFL tight ends to talk about prostate cancer screenings.

The message was loud and clear: "medicalized" wellness has gone mainstream. But amidst this cacophony of direct-to-consumer drug marketing, one major player stood out for being conspicuously quiet.

The Hims & Hers Mystery

While Ro and Wegovy were shouting about GLP-1s, telehealth giant Hims & Hers took a completely different approach. Their spot sold a democratizing message wrapped in high-gloss cinematography, suggesting that the "longevity secrets" of the 1% should be available to everyone.

But if you blinked, you might have missed what was missing.

Unlike their aggressive digital marketing of the last year, there wasn't a GLP-1 injection pen in sight. There was no direct mention of "compounded semaglutide" or the weight loss shots that have fueled the company's massive growth. While their competitors were explicitly selling the drug, Hims & Hers was selling a vibe.

This subtlety wasn't accidental. It likely reflects the shifting regulatory landscape: as of February 2026, the FDA has signaled a significant tightening of the reins on how these medications are marketed.

The Regulatory Reality Check

For the past few years, compounding pharmacies have filled a massive void. When a drug is on the FDA’s Drug Shortage List, pharmacies are legally allowed to create "essentially copies" to meet demand. This made weight loss accessible to millions who were previously priced out by $1,000/month price tags.

However, on February 6, 2026, the FDA issued a decisive statement. The agency is taking aim at "mass-marketing illegal copycat drugs." The FDA's concern is that many companies are claiming their compounded products are "generic versions" or "clinically proven" in the same way as FDA-approved drugs—which is a legal and scientific overreach.

The Crackdown: What Is Actually Changing?

The FDA is signaling that the "grace period" provided by the semaglutide shortage is evolving. Here are the three pillars of the current crackdown:

1. The "Salt" vs. "Base" Debate The FDA remains concerned that some compounders use semaglutide sodium or semaglutide acetate. The FDA-approved versions (Wegovy/Ozempic) use the base form of the drug. The agency's stance is that these salt forms are unverified variances that haven't been shown to be safe or effective in humans.

2. Misleading Marketing Claims The FDA is specifically moving against companies that market compounded GLP-1s as "FDA-approved" or "the same as" the brand-name versions. Under the law, a compounded drug is not FDA-approved; it is an unapproved drug that is permitted under specific shortage or patient-need exceptions.

3. The Complexity of Manufacturing GLP-1s are peptides—delicate biological chains. The FDA has warned that without the strict Good Manufacturing Practices (GMP) required of big pharma, there is a risk of incorrect potency or impurities. High-quality compounding pharmacies meet these standards, but the "mass-market" nature of the current boom has the FDA worried about "bad actors."

Conclusion

The 2026 Super Bowl proved that GLP-1s are now mainstream. But as the ads get flashier, the rules are getting stricter. The FDA isn't trying to take away your access to health—they are trying to ensure that when you "step into the future of medicine," you're stepping onto solid, verified ground.

Whether you choose a name-brand pill or a high-quality compounded option, your health deserves more than just a 30-second commercial. It deserves due diligence.

Disclaimer: This content is for informational purposes only and is not medical advice. Always consult your healthcare provider.